Despite the advances in harnessing the oncogenic properties of thyroid cancer via dual administration of PI3K/Akt pathway inhibitors—palbociclib and omipalisib [92]—it is not known how dysregulated miRNAs in this context could determine the drug response. This evidence concerns the gene AKT1 and thyroid cancer.